MAP2K7 and cardiofaciocutaneous syndrome: Existing mouse models of CFC syndrome recapitulate multiple human phenotypes and, together with the zebrafish models, show that MEK inhibitors, used to treat cancer, can ameliorate some of the effects of this disease.